- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 31/06 - Antibacterial agents for tuberculosis
Patent holdings for IPC class A61P 31/06
Total number of patents in this class: 1185
10-year publication summary
38
|
58
|
66
|
61
|
88
|
86
|
99
|
75
|
69
|
42
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Mondobiotech Laboratories AG | 311 |
45 |
Janssen Pharmaceutica N.V. | 3839 |
26 |
King Faisal University | 409 |
22 |
Janssen Sciences Ireland Unlimited Company | 431 |
22 |
Glaxosmithkline Intellectual Property Development Limited | 723 |
18 |
Council of Scientific & Industrial Research | 1397 |
18 |
Rutgers, The State University of New Jersey | 1776 |
11 |
Bioversys AG | 57 |
10 |
The Global Alliance for TB Drug Development, Inc. | 41 |
10 |
Otsuka Pharmaceutical Co., Ltd. | 1426 |
9 |
Glaxo Group Limited | 4496 |
8 |
Agency for Science, Technology and Research | 3512 |
8 |
AstraZeneca AB | 3042 |
7 |
Global Alliance for TB Drug Development | 9 |
7 |
Institute of Materia Medica, Chinese Academy of Medical Sciences | 165 |
7 |
Tecnimede Sociedade Tecnico-medicinal S.A. | 42 |
7 |
University of Notre Dame du Lac | 521 |
7 |
Centre National de La Recherche Scientifique | 9632 |
6 |
The Johns Hopkins University | 5377 |
6 |
Takeda Pharmaceutical Company Limited | 2961 |
6 |
Other owners | 925 |